Origami Therapeutics developing treatments for neurodegenerative diseases with ML and computational chemistry
Beth Hoffman, Origami Therapeutics CEO, talks about how the company's platform enables the discovery and development of protein degraders and conformation correctors to match the best drug to treat neurodegenerative diseases, such as Huntington's disease.